medigraphic.com
ISSN 2448-8747 (Print)
Publicación cuatrimestral editada por la Secretaría de Salud Jalisco

2023, Number S1

<< Back Next >>

Sal Jal 2023; 10 (S1)

Non-insulin therapeutic for hospitalized patients with type 2 diabetes

Gracia-Ramos AE

Language: Spanish
References: 54
Page: s23-29
PDF size: 241.48 Kb.


ABSTRACT

Hyperglycemia is a common, costly, and harmful condition for hospitalized patients with type 2 diabetes, and although standard therapy is based on the administration of insulin (mainly by means of a basal-bolus scheme), its implementation in clinical practice presents several difficulties, such as the complexity of the application schemes or the risk of hypoglycemia. Therefore, in recent years, several studies have been conducted to explore the use of non-insulin therapy in this group of patients, particularly with incretin-based therapy (dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists). This review addresses the current evidence regarding non-insulin therapy for patients with type 2 diabetes hospitalized outside the Intensive Care Unit.


REFERENCES

  1. Gracia-Ramos AE, Carretero-Gómez J, Mendez CE, Carrasco-Sánchez FJ. Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients. Curr Med Res Opin. 2022;38(1):43-53.

  2. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009;373(9677):1798-1807.

  3. Sharma S, Rayman G. Glycaemic management in patients with diabetes in hospital. Medicine. 2022;50(10):656-664.

  4. Carvalho RC, Nishi FA, Ribeiro TB, Franca GG, Aguiar PM. Association between intra-hospital uncontrolled glycemia and health outcomes in patients with diabetes: a systematic review of observational studies. Curr Diabetes Rev. 2021;17(3):304-316.

  5. Chen P, Chen L, Zhao X, Sun Q. The association of mean plasma glucose and in hospital death proportion: a retrospective, cohort study of 162,169 in-patient data. Shan PF, editor. Int J Endocrinol. 2021;2021:1513683.

  6. El-Gendy HA, Mohamed MA, Abd-Elhamid AE, Nosseir MA. Stress hyperglycemia as a prognostic factor in acute ischemic stroke patients: a prospective observational cohort study. Ain-Shams J Anesthesiol. 2021;13(1):4.

  7. Qian J, Kuang L, Che L, Chen F, Liu X. Maximum blood glucose levels during hospitalisation to predict mortality in patients with acute coronary syndrome: a retrospective cohort study. BMJ Open. 2020;10(12):e042316.

  8. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28(4):810-815.

  9. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119-1131.

  10. Malcolm J, Halperin I, Miller DB, Moore S, Nerenberg KA, Woo V, et al. In-hospital management of diabetes. Can J Diabetes. 2018;42:S115-S123.

  11. Association of British Clinical Diabetologists. Joint British Diabetes Societies (JBDS) for Inpatient Care Group [Internet]. Available in: https://abcd.care/joint-british-diabetes-societies-jbds-inpatient-care-group

  12. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 16. Diabetes care in the hospital: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S267-S278.

  13. Korytkowski MT, Muniyappa R, Antinori-Lent K, Donihi AC, Drincic AT, Hirsch IB, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2022;107(8):2101-2128.

  14. Colunga-Lozano LE, Gonzalez Torres FJ, Delgado-Figueroa N, Gonzalez-Padilla DA, Hernandez A V, Roman Y, et al. Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus. Cochrane Database Syst Rev. 2018;11(11):CD011296.

  15. Gracia-Ramos AE. Role of incretin-based therapy in hospitalized patients with type 2 diabetes. J Diabetes Investig. 2020;11(2):508-509.

  16. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642-653.

  17. Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care [Internet]. 2013;36(11):3430-3435. Available in: http://care.diabetesjournals.org/cgi/doi/10.2337/dc13-0277

  18. Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol [Internet]. 2017;5(2):125-133. Available in: https://linkinghub.elsevier.com/retrieve/pii/S2213858716304028

  19. Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, et al. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial. Diabetes Obes Metab [Internet]. 2019;21(4):837-843. Available in: https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13587

  20. Garg R, Schuman B, Hurwitz S, Metzger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care [Internet]. 2017;5(1):e000394. Available in: https://drc.bmj.com/lookup/doi/10.1136/bmjdrc-2017-000394

  21. Lyu FP, Huang BK, Su WJ, Yan FF, Zeng JY, Chen Z, et al. Efficacy of vildagliptin added to continuous subcutaneous insulin infusion (CSII) in hospitalized patients with type 2 diabetes. Diabetes Ther [Internet]. 2020;11(3):701-710. Available in: http://link.springer.com/10.1007/s13300-020-00758-5

  22. Guardado-Mendoza R, Garcia-Magaña MA, Martínez-Navarro LJ, Macías-Cervantes HE, Aguilar-Guerrero R, Suárez-Pérez EL, et al. Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection. Sci Rep. 2022;12(1):536.

  23. Petite SE, Hill MC. Evaluation of dipeptidyl peptidase-IV inhibitor use in the inpatient setting. J Pharm Pract [Internet]. 2022;35(2):229-234. Available in: http://journals.sagepub.com/doi/10.1177/0897190020966150

  24. Petite SE, Hill MC. Evaluation of dipeptidyl peptidase-iv inhibitor use in hospitalized patients with diabetes. Ann Pharmacother. 2021;55(11):1326-1332.

  25. Pérez-Belmonte L, Gómez-Doblas J, Millán-Gómez M, López-Carmona M, Guijarro-Merino R, Carrasco-Chinchilla F, et al. Use of linagliptin for the management of medicine department inpatients with type 2 diabetes in real-world clinical practice (Lina-Real-world study). J Clin Med [Internet]. 2018;7(9):271. Available in: http://www.mdpi.com/2077-0383/7/9/271

  26. Pérez-Belmonte LM, Osuna-Sánchez J, Rico-Robles JI, Ricci M, Lara JP, Gómez-Huelgas R. Simplified glycaemic management for patients with type 2 diabetes admitted for acute decompensated heart failure using linagliptin. Med Clin (Barc) [Internet]. 2022;158(4):173-177. Available in: https://linkinghub.elsevier.com/retrieve/pii/S0025775321001287

  27. Seggelke SA, Lindsay MC, Hazlett I, Sanagorski R, Eckel RH, Low Wang CC. Cardiovascular safety of antidiabetic drugs in the hospital setting. Curr Diab Rep. 2017;17(8):64.

  28. Neumiller JJ. Incretin-based therapies. Med Clin North Am. 2015;99(1):107-129.

  29. Ferro EG, Elshazly MB, Bhatt DL. New antidiabetes medications and their cardiovascular and renal benefits. Cardiol Clin. 2021;39(3):335-351.

  30. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262-276.

  31. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021:101102.

  32. Polderman JAW, van Steen SCJ, Thiel B, Godfried MB, Houweling PL, Hollmann MW, et al. Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial. Anaesthesia. 2018;73(3):332-339.

  33. Kaneko S, Ueda Y, Tahara Y. GLP1 receptor agonist liraglutide is an effective therapeutic option for perioperative glycemic control in type 2 diabetes within Enhanced Recovery After Surgery (ERAS) protocols. Eur Surg Res. 2018;59(5-6):349-360.

  34. Fayfman M, Galindo RJ, Rubin DJ, Mize DL, Anzola I, Urrutia MA, et al. A Randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care. 2019;42(3):450-456.

  35. Fushimi N, Shibuya T, Yoshida Y, Ito S, Hachiya H, Mori A. Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients. J Diabetes Investig. 2020;11(1):125-131.

  36. Ramzan S, Timmins P, Hasan SS, Babar ZU. Cost analysis of type 2 diabetes mellitus treatment in economically developed countries. Expert Rev Pharmacoecon Outcomes Res. 2019;19(1):5-14.

  37. Raphael M, Vijayanarayana K, Thunga G, Rao NK, Sreedharan N. Utilization pattern of anti-diabetic drugs in type 2 diabetes mellitus in tertiary care hospital. Res J Pharm Technol. 2017;10(7):2063.

  38. Cohen DA, Ricotta DN, Parikh PD. Things we do for no reason™: Routinely holding metformin in the hospital. J Hosp Med. 2022;17(3):207-210.

  39. Chang LL, Umpierrez GE, Inzucchi SE. Management of hyperglycemia in hospitalized, non-critically ill adults. N Engl J Med. 2022;387(11):1040-1042.

  40. Reitz KM, Marroquin OC, Zenati MS, Kennedy J, Korytkowski M, Tzeng E, et al. Association between preoperative metformin exposure and postoperative outcomes in adults with type 2 diabetes. JAMA Surg. 2020;155(6):e200416.

  41. Pasquel FJ, Hinedi Z, Umpierrez GE, Klein R, Adigweme A, Coralli R, et al. Metformin-associated lactic acidosis. Am J Med Sci. 2015;349(3):263-267.

  42. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162(4):434-437.

  43. US Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function [Internet]. 2017 [cited 2023 Mar 29]. Available in: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain

  44. Montejano L, Vo L, McMorrow D. Transitions of care for people with type 2 diabetes: utilization of antihyperglycemic agents pre- and post-hospitalization. Diabetes Ther. 2016;7(1):91-103.

  45. Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy. 2012;32(7):613-617.

  46. Rajendran R, Kerry C, Rayman G, Rayman G, Rajendran R, Kerry C, et al. Temporal patterns of hypoglycaemia and burden of sulfonylurea-related hypoglycaemia in UK hospitals: a retrospective multicentre audit of hospitalised patients with diabetes. BMJ Open. 2014;4(7):e005165-e005165.

  47. Roberts A, James J, Dhatariya K; Joint British Diabetes Societies (JBDS) for inpatient care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med. 2018;35(8):1011-1017.

  48. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386-399.

  49. Khunti K. SGLT2 inhibitors in people with and without T2DM. Nat Rev Endocrinol. 2021;17(2):75-76.

  50. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713-722.

  51. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421-4432.

  52. Gerards MC, Venema GE, Patberg KW, Kross M, Potter van Loon BJ, Hageman IMG, et al. Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease. Diabetes Obes Metab. 2018;20(5):1306-1310.

  53. Koufakis T, Mustafa OG, Ajjan RA, Garcia-Moll X, Zebekakis P, Dimitriadis G, et al. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking? J Clin Pharm Ther. 2020;45(5):883-891.

  54. US Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [Internet]. 2022 [cited 2023 Mar 29]. Available in: https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious




2020     |     www.medigraphic.com